Published January 1, 2016 | Version v1
Journal article

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity

  • 1. Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo (Japan)
  • 2. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo (Japan)
  • 3. Department of Radiation Therapy, National Cancer Center Hospital, Tokyo (Japan)

Description

Purpose: The purpose of this study was to refine the heterogeneous clinical stage IIIA non-small cell lung cancer (NSCLC) with N2 nodes status (cIIIA-N2) by clinicopathological characteristics before treatment. Methods and Materials: We analyzed data of consecutive patients with cIIIA-N2 NSCLC diagnosed between 1997 and 2010 and treated by chemoradiation therapy (CRT). The appearance of the mediastinal lymph nodes (MLNs) was classified into discrete or infiltrative according to the criteria proposed by the American College of Chest Physicians. In addition, the extent of MLN involvement (MLNI) was classified as limited (close to the primary tumor) or extensive (including upper MLNI in the case of tumors in the lower lobes and vice versa). Results: A total of 148 patients with cIIIA-N2 NSCLC was treated by CRT. The patient characteristics were as follows: males: 118; females: 30; median age: 62 years; appearance of the involved MLNs: 85 discrete, 63 infiltrative; extent of MLNI: 82 limited, 66 extensive; histology: 36 squamous, 112 nonsquamous. The median progression-free survival (PFS) and median overall survival (OS) in the entire subject population were 9.9 and 34.7 months, respectively. A discrete appearance of the involved MLNs and a limited extent of MLNI contributed significantly to a better PFS and OS. The percentages of cases with relapses within the irradiated field classified according to the characteristics of the MLNs were as follows; appearance of the MLNs (24.6% discrete, 18.9% infiltrative); extent of MLNI (25.9 limited, 17.9% extensive). Conclusions: Those with a discrete appearance of the involved MLNs and a limited extent of MLNI at diagnosis could show relatively more favorable outcomes and could be candidates for multimodality therapy.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2015.09.026

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2015.09.026;
PII
S0360-3016(15)26524-8;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
94
Journal Issue
1
Journal Page Range
p. 155-162
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
48093659
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CHEMOTHERAPY; LUNGS; LYMPH NODES; NEOPLASMS; PATIENTS
Descriptors DEC
BODY; DISEASES; LYMPHATIC SYSTEM; MEDICINE; ORGANS; RESPIRATORY SYSTEM; THERAPY

Optional Information

Copyright
Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.